[1]
Kemény, L.; Berggren, L.; Dossenbach, M.; Dutronc, Y.; Paul, C. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. J. Dermatolog. Treat., 2018, 40, 1-27.
[2]
Burda, W.N.; Fields, K.B.; Gill, J.B.; Burt, R.; Shepherd, M.; Zhang, X.P.; Shaw, L.N. Neutral metallated and meso-substituted porphyrins as antimicrobial agents against Gram-positive pathogens. Eur. J. Clin. Microbiol., 2012, 31(3), 327-335.
[3]
Bionda, N.; Fleeman, R.M.; Shaw, L.N.; Cudic, P. Effect of ester to amide or N-methylamide substitution on bacterial membrane depolarization and antibacterial activity of novel cyclic lipopeptides. ChemMedChem, 2013, 8(8), 1394-1402.
[4]
Lam, T.; Hilgers, M.T.; Cunningham, M.L.; Kwan, B.P.; Nelson, K.J.; Brown-Driver, V.; Ong, V.; Trzoss, M.; Hough, G.; Shaw, K.J.; Finn, J. Structure-based design of new dihydrofolatereductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazo-lines. J. Med. Chem., 2014, 57(3), 651-668.
[5]
T.D., Cheng; S.M., Cramb; P.D., Baade; D.R., Youlden; C., Nwogu; M.E., Reid The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J. Thorac. Oncol., 2016, 11, 1653-1671.
[6]
R.L., Siegel; K.D., Miller; A., Jemal Cancer statistics, 2016. CA Cancer J. Clin., 2016, 66, 7-30.
[7]
M.G., Kris; B.E., Johnson; L.D., Berry; D.J., Kwiatkowski; A.J., Iafrate; I.I., Wistuba; M., Varella-Garcia; W.A., Franklin; S.L., Aronson; P.F., Su; Y., Shyr; D.R., Camidge; L.V., Sequist; B.S., Glisson; F.R., Khuri; E.B., Garon; W., Pao; C., Rudin; J., Schiller; E.B., Haura; M., Socinski; K., Shirai; H., Chen; G., Giaccone; M., Ladanyi; K., Kugler; J.D., Minna; P.A., Bunn Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA, 2014, 11, 1998-2006.
[8]
Boyd, N.; Dancey, J.E.; Gilks, C.B.; Huntsman, D.G. Huntsman, Rare cancers: A sea of opportunity. Lancet Oncol., 2016, 17, e52-e61.
[9]
Olaussen, K.A.; Postel-Vinay, S. Predictors of chemotherapy efficacy in non-smallcell lung cancer: A challenging landscape. Ann. Oncol., 2016, 27, 2004-2016.
[10]
1000 Genomes Project Consortium; Abecasis, G.R.; Auton, A.; Brooks, L.D.; DePristo, M.A.; Durbin, R.M.; Handsaker, R.E.; Kang, H.M.; Marth, G.T.; McVean, G.A. An integrated map of genetic variation from 1092 human genomes. Nature, 2012, 491, 56-65.
[11]
Li, L.C.; Jayarama, S.; Pilli, T.; Qian, L.; Pacini, F.; Prabhakar, B.S. Down Modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand resistant thyroid cancer cells makes them susceptible to treatment with this ligand. Thyroid, 2013, 23, 70-78.
[12]
Oh, Y.T.; Deng, J.; Yue, P.; Owonikoko, T.K.; Khuri, F.R. Sun. S.Y. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. Oncogene, 2016, 35, 459-467.
[13]
Jin, S.M.; Jang, H.W.; Sohn, S.Y.; Kim, N.K.; Joung, J.Y.; Cho, Y.Y.; Kim, S.W.; Chung, J.H. Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells. Endocrine, 2014, 45, 256-262.
[14]
Choi, D.; Ramu, S.; Park, E.; Jung, E.; Yang, S.; Jung, W.; Choi, I.; Lee, S.; Kim, K.E.; Seong, Y.J.; Hong, M.; Daghlian, G.; Kim, D.; Shin, E.; Seo, J.I.; Khatchadourian, V.; Zou, M.; Li, W.; De Filippo, R.; Kokorowski, P.; Chang, A.; Kim, S.; Bertoni, A.; Furlanetto, T.W.; Shin, S.; Li, M.; Chen, Y.; Wong, A.; Koh, C.; Geliebter, J.; Hong, Y.K. Aberrant activation of Notch signaling inhibits PROX1 activity to enhance the malignant behavior of thyroid cancer cells. Cancer Res., 2016, 76, 582-593.
[15]
Somnay, Y.R.; Yu, X.M.; Lloyd, R.V.; Leverson, G.; Aburjania, Z.; Jang, S.; Jaskula-Sztul, R.; Chen, H. Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis. Cancer, 2017, 123, 769-782.
[16]
Jaskula-Sztul, R.; Eide, J.; Tesfazghi, S.; Dammalapati, A.; Harrison, A.D.; Yu, X.M.; Scheinebeck, C.; Winston-McPherson, G.; Kupcho, K.R.; Robers, M.B.; Hundal, A.K.; Tang, W.; Chen, H. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction. Mol. Cancer Ther., 2015, 14, 499-512.
32
5